Our mission is to make fundamental discoveries relating to hormone signaling, transcriptional control and host-pathogen interactions. We leverage these discoveries to pursue drug design as treatments for viral infections and chronic inflammatory diseases. We use a range of sophisticated biological techniques including cryo-electron microscopy, x-ray crystallography, mass spectrometry, deep mutational scanning and in silico simulations. Our primary research interests include lipid-mediated signaling and transport, development of LRH-1 modulators to treat metabolic disease, characterization of anti-inflammatory steroids and molecular evolution. With the outbreak of SARS-CoV-2, we were well-placed to redirect our expertise to investigate detection and neutralizing antibodies using Cryo-EM, and to predict antibody escape using deep mutational scanning (DMS). Working closely with the RADx initiative, our methods have proven useful to multiple companies seeking FDA approval for their novel COVID-19 diagnostic methods. Currently we are expanding our technology to tackle other arising infectious diseases of concern.